Xinlitai "Dapositin hydrochloric acid tablets" will soon be approved

On October 18, PharmaGo, a database of pharmaceutical Rubik's Cubes, showed that Xinlitai's declared application for the listing of four classes of generic drug dapoxitin hydrochloric acid entered the "approval" stage and is expected to be approved in the near future.
hydrochloric acid dapositin is a short-acting selective 5-serotonin reuptake inhibitor, the original research manufacturer for Johnson and Johnson, mainly suitable for the treatment of 18-64 years old male premature ejaculation patients.
(PE) is a common male sexual dysfunction disease with a high incidence, which has a serious impact on the physical and mental health and quality of life of patients.
hydrochloric acid dapoxitin is currently the only approved chemical drug for the treatment of premature ejaculation, but also at home and abroad, "early ejaculation diagnosis and treatment guidelines" the first line of treatment drugs, its clinical benefits are good, and low safety risk, with rapid effectiveness, rapid removal and low drug accumulation and other advantages.
Ofa Platinum Kaisheng Bio and Collum Pharmaceuticals' Dapostin have been approved in China, as if through a consistent evaluation, and in the third batch of national harvest successfully won the bid.